NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other languages
Dutch (nl)
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (US07585860-20090908-C00083.png) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (US07585860-20090908-C00083.png)
EP (6) EP1162999B1 (US07585860-20090908-C00083.png)
JP (4) JP4846906B2 (US07585860-20090908-C00083.png)
KR (3) KR100798212B1 (US07585860-20090908-C00083.png)
CN (3) CN100339130C (US07585860-20090908-C00083.png)
AR (3) AR022963A1 (US07585860-20090908-C00083.png)
AT (3) ATE346608T1 (US07585860-20090908-C00083.png)
AU (3) AU750762B2 (US07585860-20090908-C00083.png)
BE (1) BE1025464I2 (US07585860-20090908-C00083.png)
BR (4) BR0009166A (US07585860-20090908-C00083.png)
CA (3) CA2365296A1 (US07585860-20090908-C00083.png)
CY (3) CY1107561T1 (US07585860-20090908-C00083.png)
CZ (3) CZ20013378A3 (US07585860-20090908-C00083.png)
DE (4) DE60038166T2 (US07585860-20090908-C00083.png)
DK (2) DK1163000T3 (US07585860-20090908-C00083.png)
ES (3) ES2275499T3 (US07585860-20090908-C00083.png)
FR (1) FR10C0008I2 (US07585860-20090908-C00083.png)
HK (3) HK1043730A1 (US07585860-20090908-C00083.png)
HU (4) HU228499B1 (US07585860-20090908-C00083.png)
IL (5) IL145044A0 (US07585860-20090908-C00083.png)
LU (1) LU91652I2 (US07585860-20090908-C00083.png)
MX (1) MXPA01009452A (US07585860-20090908-C00083.png)
MY (2) MY125387A (US07585860-20090908-C00083.png)
NL (1) NL300415I1 (US07585860-20090908-C00083.png)
NO (4) NO330532B1 (US07585860-20090908-C00083.png)
NZ (3) NZ513840A (US07585860-20090908-C00083.png)
PL (3) PL203917B1 (US07585860-20090908-C00083.png)
PT (2) PT1163000E (US07585860-20090908-C00083.png)
SI (2) SI1162999T1 (US07585860-20090908-C00083.png)
TR (3) TR200102739T2 (US07585860-20090908-C00083.png)
TW (3) TWI235064B (US07585860-20090908-C00083.png)
WO (3) WO2000056359A2 (US07585860-20090908-C00083.png)

Families Citing this family (268)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
NZ560966A (en) 2000-10-27 2010-06-25 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
KR100982204B1 (ko) 2001-12-12 2010-09-14 ė…øė°”ķ‹°ģŠ¤ ė°±ģ‹ ģ¦ˆ ģ•¤ė“œ ė‹¤ģ“ģ•„ź·øė…øģŠ¤ķ‹±ģŠ¤ ģ—ģŠ¤.ģ•Œ.ģ—˜. ķ“ė¼ėÆøė””ģ•„ ķŠøė¼ģ½”ė§ˆķ‹°ģŠ¤ģ— ėŒ€ķ•œ ė©“ģ—­ķ™”
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
MXPA04011248A (es) * 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
SI1549338T1 (sl) 2002-10-11 2011-04-29 Novartis Vaccines & Diagnostic Polipeptidna cepiva za Äŗ iroko zaÄŗ Ć¤Å›ito pred hipervirulentnimi miningokoknimi rodovi
AU2003274011B2 (en) * 2002-10-15 2010-03-04 Intercell Ag Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
ES2649048T3 (es) 2002-11-01 2018-01-09 Glaxosmithkline Biologicals S.A. Procedimiento de secado
CN100351260C (zh) 2002-11-12 2007-11-28 åøƒčµ–ę±‰å§†å¦‡å„³åŒ»é™¢ 葔萄ēƒčŒę„ŸęŸ“ēš„多ē³–ē–«č‹—
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
ES2411080T3 (es) * 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra mĆŗltiples serogrupos de meningococos
BRPI0408167B1 (pt) * 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarĆ­deo-proteĆ­na veĆ­culo adesina da superfĆ­cie estafilocĆ³cica para imunizaĆ§Ć£o contra infecƧƵes nosocomiais
ES2295836T3 (es) * 2003-03-13 2008-04-16 Glaxosmithkline Biologicals S.A. Procedimiento de purificacion de citolisina bacteriana.
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
JP5557415B2 (ja) 2003-06-02 2014-07-23 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ 惐ć‚Æć‚·ćƒ³ć‚ŗ ć‚¢ćƒ³ćƒ‰ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ćƒƒć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ åøē€ć•ć›ćŸćƒˆć‚­ć‚½ć‚¤ćƒ‰ćŠć‚ˆć³å¤šē³–é”žå«ęœ‰ęŠ—åŽŸć‚’å«ć‚€å¾®ē²’å­ć«åŸŗć„ćå…ē–«åŽŸę€§ēµ„ęˆē‰©
PL1961426T3 (pl) * 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mĆ³zgowo-rdzeniowych
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP2277595A3 (en) 2004-06-24 2011-09-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US20060165716A1 (en) 2004-07-29 2006-07-27 Telford John L Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
NZ555937A (en) 2005-01-27 2009-05-31 Childrens Hosp & Res Ct Oak GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgŔtys iŔ su meningitu/sepsiu susijusių escherichia coli
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2604363C (en) * 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2605179A1 (en) 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
NZ564606A (en) 2005-06-27 2010-10-29 Glaxosmithkline Biolog Sa Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein
WO2007026249A2 (en) 2005-09-01 2007-03-08 Novartis Vaccines And Diagnostics Gmbh & Co Kg Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. PartĆ­culas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
NO346529B1 (no) * 2005-12-22 2022-09-26 Glaxosmithkline Biologicals Sa Bruk av et immunogenpreparat for smƄbarn, omfattende 22F sakkaridkonjugat
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
MY150105A (en) * 2006-01-17 2013-11-29 Forsgren Arne A novel surface exposed haemophilus influenzae protein (protein e; pe)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
BRPI0708849B1 (pt) * 2006-03-17 2022-05-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services MĆ©todos para a preparaĆ§Ć£o de conjugados imunogĆŖnicos multivalentes complexos, os referidos conjugados, e composiƧƵes farmacĆŖuticas
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
JP2009531387A (ja) * 2006-03-30 2009-09-03 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
PE20080129A1 (es) * 2006-03-30 2008-04-08 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
EP2035035A2 (en) * 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP2010500399A (ja) 2006-08-16 2010-01-07 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ å°æč·Æē—…åŽŸę€§å¤§č…ø菌ē”±ę„ć®å…ē–«åŽŸ
RU2460539C2 (ru) * 2006-10-10 2012-09-10 Š’Š°Š¹ŠµŃ‚ Š”ŠŸŠžŠ”ŠžŠ‘ ŠžŠ§Š˜Š”Š¢ŠšŠ˜ ŠŸŠžŠ›Š˜Š”ŠŠ„ŠŠ Š˜Š”ŠžŠ’ Streptococcus pneumoniae 3 Š¢Š˜ŠŸŠ (Š’ŠŠ Š˜ŠŠŠ¢Š«)
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CN101883583B (zh) * 2007-06-26 2017-05-17 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø å«ęœ‰č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–ē¼€åˆē‰©ēš„ē–«č‹—
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
DK2200642T3 (da) 2007-10-19 2012-07-16 Novartis Ag MeningococvaccineprƦparater
JP2011503104A (ja) 2007-11-09 2011-01-27 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 免ē–«čŖæēƀ化合ē‰©ćŖć‚‰ć³ć«é–¢é€£ēµ„ęˆē‰©ćŠć‚ˆć³ę–¹ę³•
EP3067048B1 (en) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions for inducing immune responses
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
CN102356089B (zh) 2008-02-21 2014-02-19 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒfHBPå¤šč‚½
WO2009114485A2 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
BRPI0916365A2 (pt) 2008-07-21 2018-05-02 Brigham & Womens Hospital Inc mƩtodos e composiƧƵes relacionados aos oligossacarƭdeos de glicosina beta-1,6 sintƩticos
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiŔčenja za ogljikohidrat iz Streptococcus skupine A
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
JP2012512240A (ja) 2008-12-17 2012-05-31 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒ˜ćƒ¢ć‚°ćƒ­ćƒ“ćƒ³å—å®¹ä½“ć‚’å«ć‚€é«„č†œē‚ŽčŒćƒÆć‚Æćƒćƒ³
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
CN103897045A (zh) 2009-01-12 2014-07-02 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø ęŠ—é©å…°ę°é˜³ę€§ē»†čŒē–«č‹—äø­ēš„Cna_Bē»“ęž„åŸŸ
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa AdjuvĆ”lĆ³ H meningococcus faktort kƶtƵ fehĆ©rje
WO2010109324A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag ComposiĆ§Ć£o imunogĆŖnica Ćŗtil para imunizaĆ§Ć£o contra staphylococcus aureus, seu mĆ©todo de preparaĆ§Ć£o e composiĆ§Ć£o farmacĆŖutica
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
EP3461496B1 (en) 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
MX2012000044A (es) 2009-06-22 2012-01-30 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
CA2772104A1 (en) 2009-08-27 2011-03-03 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CN104548089B (zh) 2009-09-03 2017-09-26 č¾‰ē‘žē–«č‹—ęœ‰é™č“£ä»»å…¬åø Pcsk9ē–«č‹—
CN102695523A (zh) 2009-09-10 2012-09-26 čÆŗåŽęœ‰é™å…¬åø 针åƹ呼åø道ē–¾ē—…ēš„ē»„合ē–«č‹—
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptĆ­deos de modificaĆ§Ć£o meningocĆ³cica fhbp"
PL2493498T3 (pl) 2009-10-30 2017-08-31 Glaxosmithkline Biologicals Sa Oczyszczanie sacharydĆ³w otoczkowych staphylococcus aureus typu 5 i typu 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US9044517B2 (en) 2009-12-17 2015-06-02 Fina Biosolutions, Llc Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
JP6007105B2 (ja) 2009-12-22 2016-10-12 ć‚»ćƒ«ćƒ‡ćƒƒć‚Æć‚¹ćƒ»ć‚»ćƒ©ćƒ”ćƒ„ćƒ¼ćƒ†ć‚£ć‚Æć‚¹ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ćƒÆć‚Æćƒćƒ³ēµ„ęˆē‰©
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
CA2790167C (en) 2010-03-30 2021-02-09 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2555753B1 (en) 2010-04-07 2018-08-01 California Institute of Technology Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2011146910A1 (en) * 2010-05-20 2011-11-24 Round June L Antigen specific tregs and related compositions, methods and systems
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
SI3170508T1 (sl) * 2010-06-04 2020-01-31 Wyeth Llc Formulacije cepiva
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2011154863A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
ES2612511T3 (es) 2011-01-27 2017-05-17 Glaxosmithkline Biologicals Sa Nanoemulsiones de adyuvante con inhibidores de cristalizaciĆ³n
ES2681698T3 (es) 2011-03-02 2018-09-14 Glaxosmithkline Biologicals Sa Vacunas de combinaciĆ³n con menores dosis de antĆ­geno y/o adyuvante
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
WO2012154072A1 (ru) 2011-05-06 2012-11-15 Aparin Petr Gennadievich Š­ŠŗŠ·Š¾ŠæŠ¾Š»ŠøсŠ°Ń…Š°Ń€ŠøŠ“ Š±Š°ŠŗтŠµŃ€ŠøŠø shigella sonnei, сŠæŠ¾ŃŠ¾Š± ŠµŠ³Š¾ ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Šø Š²ŠŗŠ»ŃŽŃ‡Š°ŃŽŃ‰ŠøŠµ ŠµŠ³Š¾ Š²Š°ŠŗцŠøŠ½Š° Šø фŠ°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøя
AU2012272652B2 (en) 2011-06-24 2017-06-01 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
JP6088507B2 (ja) 2011-07-08 2017-03-01 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒćƒ­ć‚·ćƒ³ćƒ©ć‚¤ć‚²ćƒ¼ć‚·ćƒ§ćƒ³ć®ę–¹ę³•
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
WO2013043518A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
MX354924B (es) 2011-11-07 2018-03-22 Novartis Ag Molecula portadora que comprende un antigeno spr0096 y un spr2021.
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
RU2014127714A (ru) 2011-12-08 2016-01-27 ŠŠ¾Š²Š°Ń€Ń‚Šøс ŠŠ³ Š’ŠŠšŠ¦Š˜ŠŠ ŠŠ ŠžŠ”ŠŠžŠ’Š• Š¢ŠžŠšŠ”Š˜ŠŠžŠ’ Clostridium difficile
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ é«„č†œē‚ŽčŒļ½ˆå› å­ēµåˆć‚æćƒ³ćƒ‘ć‚Æč³Ŗć®ć‚¢ć‚øćƒ„ćƒćƒ³ćƒˆć•ć‚ŒćŸēµ„ćæåˆć‚ć›
WO2013124473A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
JP2015510872A (ja) 2012-03-07 2015-04-13 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼³ļ½”ļ½’ļ½…ļ½ļ½”ļ½ļ½ƒļ½ļ½ƒļ½ƒļ½•ļ½“ļ½ļ½Žļ½…ļ½•ļ½ļ½ļ½Žļ½‰ļ½ļ½…ęŠ—åŽŸć®å¢—å¼·ć•ć‚ŒćŸč£½å‰¤
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
BR112014026812A8 (pt) 2012-04-26 2022-10-04 Novartis Ag Antƭgenos e combinaƧƵes de antƭgenos
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
CN107746852B (zh) 2012-05-04 2021-10-08 č¾‰ē‘žå…¬åø 前列č…ŗē›øå…³ęŠ—åŽŸåŠåŸŗäŗŽē–«č‹—ēš„免ē–«ę²»ē–—ē–—ę³•
JP2015518845A (ja) 2012-05-22 2015-07-06 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ é«„č†œē‚ŽčŒč”€ęø…ē¾¤ļ½˜ć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆ
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
EP2892553A1 (en) 2012-09-06 2015-07-15 Novartis AG Combination vaccines with serogroup b meningococcus and d/t/p
ES2848048T3 (es) 2012-10-03 2021-08-05 Glaxosmithkline Biologicals Sa Composiciones inmunogƩnicas
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
EP2908856B1 (en) * 2012-10-17 2019-02-20 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
WO2014118305A1 (en) 2013-02-01 2014-08-07 Novartis Ag Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP2994161B1 (en) 2013-05-10 2020-10-28 California Institute of Technology Probiotic prevention and treatment of colon cancer
JP2016520077A (ja) 2013-05-15 2016-07-11 悶 ć‚¬ćƒćƒŠćƒ¼ć‚ŗ ć‚Ŗ惖 悶 ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ ć‚Ŗ惖 ć‚¢ćƒ«ćƒćƒ¼ć‚æ ļ¼„ļ¼‘ļ½…ļ¼’ļ½ˆļ½ƒļ½–ćƒÆć‚Æćƒćƒ³åŠć³ä½æē”Øę–¹ę³•
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
NZ759686A (en) 2014-01-21 2023-07-28 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN105934251A (zh) 2014-01-21 2016-09-07 č¾‰ē‘žå¤§čÆ厂 č‚ŗē‚Žé“¾ēƒčŒčšč†œå¤šē³–及其ē¼€åˆē‰©
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
HUE052293T2 (hu) 2014-02-28 2021-04-28 Glaxosmithkline Biologicals Sa MĆ³dosĆ­tott fHbp meningococcus-polipeptidek
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteĆ­na de ligaĆ§Ć£o ao fator h (fhbp), composiĆ§Ć£o imunogĆŖnica e uso de uma fhbp variante referĆŖncia cruzada
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
HUE062499T2 (hu) 2015-01-15 2023-11-28 Pfizer Pneumococcus-vakcinĆ”kban tƶrtĆ©nƵ alkalmazĆ”sra szolgĆ”lĆ³ immunogĆ©n kĆ©szĆ­tmĆ©nyek
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
RU2721128C2 (ru) 2015-07-21 2020-05-18 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, сŠ¾Š“ŠµŃ€Š¶Š°Ń‰ŠøŠµ ŠŗŠ¾Š½ŃŠŃŽŠ³ŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ Š°Š½Ń‚ŠøŠ³ŠµŠ½Ń‹ ŠŗŠ°ŠæсуŠ»ŃŒŠ½Š¾Š³Š¾ сŠ°Ń…Š°Ń€ŠøŠ“Š°, Š½Š°Š±Š¾Ń€Ń‹, сŠ¾Š“ŠµŃ€Š¶Š°Ń‰ŠøŠµ этŠø ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
PE20181158A1 (es) 2015-12-04 2018-07-19 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer
PT3405212T (pt) 2016-01-19 2020-08-25 Pfizer Vacinas para o cancro
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
EP3474890A1 (en) * 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Fƶrderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
MX2019001341A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de polisacarido neumococico multivalente-proteina.
MX2019001342A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de proteina-polisacarido de neumococo multivalente.
EP3506933A2 (en) 2016-09-02 2019-07-10 GlaxoSmithKline Biologicals SA Vaccines for neisseria gonorrhoeae
EP3522915A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
CN117801069A (zh) 2016-10-07 2024-04-02 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
RU2762723C2 (ru) 2017-01-20 2021-12-22 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Š“Š»Ń ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя Š² ŠæŠ½ŠµŠ²Š¼Š¾ŠŗŠ¾ŠŗŠŗŠ¾Š²Ń‹Ń… Š²Š°ŠŗцŠøŠ½Š°Ń…
CN118021947A (zh) 2017-01-31 2024-05-14 č¾‰ē‘žå¤§čÆ厂 脑膜ē‚Žå„ˆē‘ŸčŒē»„合ē‰©åŠå…¶ä½æē”Øę–¹ę³•
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110520154B (zh) * 2017-03-15 2023-08-04 ę Ŗ式会ē¤¾Lg化学 多价č‚ŗē‚Žé“¾ēƒčŒē–«č‹—ē»„合ē‰©
JP2020515587A (ja) 2017-03-31 2020-05-28 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ć€ć‚¤ćƒ³ćƒ†ćƒ¬ć‚Æćƒćƒ„ć‚¢ćƒ«ć€ćƒ—ćƒ­ćƒ‘ćƒ†ć‚£ćƒ¼ć€ćƒ‡ć‚£ćƒ™ćƒ­ćƒƒćƒ—ćƒ”ćƒ³ćƒˆć€ćƒŖ惟惆惃惉ļ¼§ļ½Œļ½ļ½˜ļ½ļ½“ļ½ļ½‰ļ½”ļ½ˆļ½‹ļ½Œļ½‰ļ½Žļ½… ļ¼©ļ½Žļ½”ļ½…ļ½Œļ½Œļ½…ļ½ƒļ½”ļ½•ļ½ļ½Œ ļ¼°ļ½’ļ½ļ½ļ½…ļ½’ļ½”ļ½™ ļ¼¤ļ½…ļ½–ļ½…ļ½Œļ½ļ½ļ½ļ½…ļ½Žļ½” ļ¼¬ļ½‰ļ½ļ½‰ļ½”ļ½…ļ½„ 免ē–«åŽŸę€§ēµ„ęˆē‰©ć€ä½æē”ØåŠć³å‡¦ē½®ę–¹ę³•
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
KR20240018698A (ko) 2017-06-10 2024-02-13 ģøė²¤ķŠøķ”„ė¼ģ“ģ¦ˆ ģøķ¬. ė©“ģ—­ģ›ģ„±ź³¼ ķ•­ģ›ķ•­ģ²“ ź²°ķ•©ģ„±ģ“ ź°œģ„ ėœ 2ź°€ ė˜ėŠ” ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė‹¤ė‹¹ė„˜ė„¼ ź°€ģ§„ ė‹¤ź°€ ģ ‘ķ•©ģ²“ ė°±ģ‹ 
WO2019034575A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa METHODS OF AMPLIFYING IMMUNE RESPONSES
AR114154A1 (es) 2017-12-06 2020-07-29 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacƔrido de streptococcus pneumoniae con proteƭna y mƩtodos de uso de estos
IL276229B2 (en) 2018-02-05 2024-01-01 Sanofi Pasteur Inc A multivalent pneumococcal protein-polysaccharide conjugate preparation
SG11202006388SA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20210113678A1 (en) 2018-04-11 2021-04-22 Enterome S.A. Antigenic Peptides For Prevention And Treatment Of Cancer
EP3773673A2 (en) 2018-04-11 2021-02-17 Enterome S.A. Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
WO2019203599A1 (ko) 2018-04-18 2019-10-24 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ķ˜‘ė§‰ ė‹¤ė‹¹ė„˜ ė° ź·øģ˜ ė©“ģ—­ģ›ģ„± ģ ‘ķ•©ģ²“
EP3824019A1 (en) 2018-07-19 2021-05-26 GlaxoSmithKline Biologicals SA Processes for preparing dried polysaccharides
CA3107077A1 (en) 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP2022513458A (ja) 2018-12-12 2022-02-08 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ļ¼Æļ¼ēµåˆåž‹ć‚°ćƒŖć‚³ć‚·ćƒ«åŒ–ć®ćŸć‚ć®äæ®é£¾ć‚­ćƒ£ćƒŖć‚¢ć‚æćƒ³ćƒ‘ć‚Æč³Ŗ
CA3123414A1 (en) 2018-12-19 2020-06-25 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
WO2020208502A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
CA3139257A1 (en) 2019-05-10 2020-11-19 Glaxosmithkline Biologicals Sa Conjugate production
CA3148928A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
AU2020325645A1 (en) 2019-08-05 2022-02-17 Glaxosmithkline Biologicals Sa Immunogenic composition
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021074389A1 (en) 2019-10-16 2021-04-22 Enterome S.A. Immunogenic compounds for treatment of adrenal cancer
CN114667343A (zh) 2019-11-01 2022-06-24 č¾‰ē‘žå¤§čÆ厂 å¤§č‚ ę†čŒē»„合ē‰©åŠå…¶ę–¹ę³•
HUE065075T2 (hu) 2019-11-15 2024-04-28 Enterome S A AntigƩn peptidek B-sejtes malignitƔs megelƵzƩsƩre Ʃs kezelƩsƩre
MX2022006054A (es) 2019-11-22 2022-06-24 Glaxosmithkline Biologicals Sa Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
US20230085173A1 (en) 2020-02-21 2023-03-16 Pfizer Inc. Purification of saccharides
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer ComposiƧƵes de escherichia coli e mƩtodos das mesmas.
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
AU2021368151A1 (en) 2020-10-27 2023-06-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN116744965A (zh) 2020-11-04 2023-09-12 č¾‰ē‘žå¤§čÆ厂 ē”ØäŗŽč‚ŗē‚ŽēƒčŒē–«č‹—ēš„免ē–«åŽŸę€§ē»„合ē‰©
EP4243863A2 (en) 2020-11-10 2023-09-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
WO2022178196A1 (en) 2021-02-19 2022-08-25 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
WO2022175423A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Biologicals Sa Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer ComposiƧƵes imunogĆŖnicas compreendendo antĆ­genos de sacarĆ­deo capsular conjugados e usos dos mesmos
US20220387576A1 (en) 2021-05-28 2022-12-08 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3237496A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230116601A (ko) 2022-01-28 2023-08-04 ģ“ė™ėƼ ėØøģ‹  ģ¢Œķ‘œź³„ģ™€ ģ˜ģƒ ģ¢Œķ‘œź³„ģ˜ ģ •ķ•© ė°©ė²• ė° ģž„ģ¹˜
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
RU2121481C1 (ru) * 1988-12-16 1998-11-10 Š”Šµ Š”тŠ°Ń‚ Š”ŠµŃ€ ŠŠµŠ“ŠµŃ€Š»Š°Š½Š“ŠµŠ½ Š’ŠµŃ€Ń‚ŠµŠ³ŠµŠ½Š²Š¾Ń€Š“ŠøŠ³Š“ Š”Š¾Ń€ Š“Šµ ŠœŠøŠ½Šøстр Š’Š°Š½ Š’ŠµŠ»Š·ŠµŠ¹Š½, Š’Š¾Š»ŠŗсŠ³ŠµŠ·Š¾Š½Š“хŠµŠ¹Š“ эŠ½ ŠšŃŽŠ»Ń‚ŃŽŃ€ ŠœŠ¾Š“ŠøфŠøцŠøрŠ¾Š²Š°Š½Š½Ń‹Š¹ ŠæŠ½ŠµŠ²Š¼Š¾Š»ŠøŠ·ŠøŠ½, рŠµŠŗŠ¾Š¼Š±ŠøŠ½Š°Š½Ń‚Š½Š°Ń ŠæŠ»Š°Š·Š¼ŠøŠ“Š°, сŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Š¼Š¾Š“ŠøфŠøцŠøрŠ¾Š²Š°Š½Š½Š¾Š³Š¾ ŠæŠ½ŠµŠ²Š¼Š¾Š»ŠøŠ·ŠøŠ½Š°, Š²Š°ŠŗцŠøŠ½Š°
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
ATE211654T1 (de) * 1992-09-16 2002-01-15 Univ Tennessee Res Corp Antigene des hybriden m-proteins und trƤger fĆ¼r gruppe a streptokokkenimpfstoff
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
WO1994026304A1 (en) 1993-05-18 1994-11-24 Ohio State Research Foundation Otitis media vaccine
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
NZ306316A (en) * 1995-04-17 2001-06-29 Smithkline Beecham Biolog S use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
UA56132C2 (uk) 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
CZ394297A3 (cs) 1995-06-07 1998-04-15 Biochem Vaccines Inc. StreptokokovĆ© proteiny teplotnĆ­ho Å”oku ze skupiny HSP70
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
HUP9802199A3 (en) 1995-06-07 1999-07-28 Smithkline Beecham Biolog Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein and use of
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
AU732520B2 (en) 1996-05-01 2001-04-26 Rockefeller University, The Choline binding proteins for anti-pneumococcal vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
JP2001502925A (ja) 1997-06-03 2001-03-06 ć‚³ćƒŽćƒ¼ćƒˆ ćƒ©ćƒœćƒ©ćƒˆćƒŖćƒ¼ć‚ŗ ćƒŖ惟惆惃惉 ćƒ¢ćƒ©ć‚Æć‚»ćƒ©ć®ćƒ©ć‚Æ惈惕悧ćƒŖćƒ³å—å®¹ä½“éŗ伝子
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
BR9909483A (pt) 1998-04-07 2001-10-09 Medimmune Inc Derivados de proteƬnas ligantes pneumococcal colina para vacinas
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
AU771330B2 (en) 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
WO2000037105A2 (en) * 1998-12-21 2000-06-29 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
AU3430700A (en) 2000-10-09
CA2366314A1 (en) 2000-09-28
DE60038166T2 (de) 2009-03-12
HK1043731B (zh) 2009-01-23
MY125202A (en) 2006-07-31
NO330736B1 (no) 2011-06-27
HK1043731A1 (en) 2002-09-27
KR100798212B1 (ko) 2008-01-24
CA2365296A1 (en) 2000-09-28
IL145044A (en) 2007-03-08
KR20020001785A (ko) 2002-01-09
HK1043730A1 (zh) 2002-09-27
WO2000056359A2 (en) 2000-09-28
US20110217329A1 (en) 2011-09-08
JP2002539273A (ja) 2002-11-19
KR20020000549A (ko) 2002-01-05
CZ303653B6 (cs) 2013-01-30
ATE346608T1 (de) 2006-12-15
CY1107390T1 (el) 2010-07-28
ES2339737T3 (es) 2010-05-25
AR022964A1 (es) 2002-09-04
NO20014323L (no) 2001-11-14
AU750788B2 (en) 2002-07-25
WO2000056358A3 (en) 2001-01-04
CA2366152A1 (en) 2000-09-28
IL145043A0 (en) 2002-06-30
CY2009014I1 (el) 2010-07-28
CN1191852C (zh) 2005-03-09
HUP0200367A2 (en) 2002-05-29
US9168313B2 (en) 2015-10-27
JP2002540075A (ja) 2002-11-26
CZ20013378A3 (cs) 2002-03-13
FR10C0008I1 (fr) 2010-03-26
US20100119544A1 (en) 2010-05-13
TWI281403B (en) 2007-05-21
NL300415I1 (nl) 2009-12-01
CN1192798C (zh) 2005-03-16
JP4846906B2 (ja) 2011-12-28
NO20014323D0 (no) 2001-09-05
BRPI0009163B1 (pt) 2019-04-09
HUS1500040I1 (hu) 2018-05-28
CN1351501A (zh) 2002-05-29
NO20014322D0 (no) 2001-09-05
DE60032120D1 (de) 2007-01-11
LU91652I2 (fr) 2010-10-13
KR100642044B1 (ko) 2006-11-10
AU3813600A (en) 2000-10-09
EP2277535A2 (en) 2011-01-26
CZ20013379A3 (cs) 2002-03-13
JP2002540074A (ja) 2002-11-26
DE122009000054I1 (de) 2009-12-31
CY2009014I2 (el) 2010-07-28
NZ513842A (en) 2004-05-28
PL204890B1 (pl) 2010-02-26
DK1163000T3 (da) 2008-04-28
PT1162999E (pt) 2007-02-28
ATE459373T1 (de) 2010-03-15
DE60038166D1 (de) 2008-04-10
EP1162999A2 (en) 2001-12-19
PL355180A1 (en) 2004-04-05
BRPI0009163B8 (pt) 2021-05-25
TWI235064B (en) 2005-07-01
EP1162999B1 (en) 2006-11-29
TR200102735T2 (tr) 2002-04-22
IL145044A0 (en) 2002-06-30
TR200102736T2 (tr) 2002-04-22
US20050031646A1 (en) 2005-02-10
DE60043930D1 (de) 2010-04-15
FR10C0008I2 (fr) 2012-10-26
NZ513841A (en) 2001-09-28
EP2277535A3 (en) 2011-03-09
EP1880735A2 (en) 2008-01-23
AU3291900A (en) 2000-10-09
KR20020000785A (ko) 2002-01-05
CN1391481A (zh) 2003-01-15
PL355178A1 (en) 2004-04-05
US20060093626A1 (en) 2006-05-04
DK1162999T3 (da) 2007-03-26
NO20014322L (no) 2001-11-14
MY125387A (en) 2006-07-31
HK1043728A1 (en) 2002-09-27
NZ513840A (en) 2004-02-27
BR0009154A (pt) 2001-12-26
MXPA01009452A (es) 2002-08-06
DE60032120T2 (de) 2007-09-20
BR0009166A (pt) 2001-12-26
EP1163000A2 (en) 2001-12-19
PL355264A1 (en) 2004-04-05
AR022965A1 (es) 2002-09-04
ES2300255T3 (es) 2008-06-16
AR022963A1 (es) 2002-09-04
NO20014325D0 (no) 2001-09-05
EP1162998B1 (en) 2010-03-03
AU750913B2 (en) 2002-08-01
CZ301445B6 (cs) 2010-03-03
CA2366314C (en) 2012-01-10
SI1163000T1 (sl) 2008-06-30
CY1107561T1 (el) 2013-03-13
HUP0200664A2 (en) 2002-06-29
PT1163000E (pt) 2008-03-20
US20100291138A1 (en) 2010-11-18
BE1025464I2 (US07585860-20090908-C00083.png) 2019-03-06
US20030147922A1 (en) 2003-08-07
HU229968B1 (hu) 2015-03-30
US20150079125A1 (en) 2015-03-19
EP1162998A2 (en) 2001-12-19
WO2000056359A3 (en) 2001-02-01
WO2000056360A3 (en) 2001-01-25
HK1043728B (zh) 2007-06-22
NO20014325L (no) 2001-11-14
LU91652I9 (US07585860-20090908-C00083.png) 2019-01-03
AU750762B2 (en) 2002-07-25
WO2000056358A2 (en) 2000-09-28
NO2011014I1 (no) 2011-09-19
CN100339130C (zh) 2007-09-26
TWI286938B (en) 2007-09-21
ATE387214T1 (de) 2008-03-15
JP2011057713A (ja) 2011-03-24
BR0009163A (pt) 2001-12-26
HUP0200373A2 (en) 2002-06-29
NO2011014I2 (no) 2011-08-30
US20060002961A1 (en) 2006-01-05
CN1351503A (zh) 2002-05-29
JP5551579B2 (ja) 2014-07-16
WO2000056360A2 (en) 2000-09-28
US8926985B2 (en) 2015-01-06
IL145045A0 (en) 2002-06-30
EP1880735A3 (en) 2008-03-12
EP1163000B1 (en) 2008-02-27
HU228499B1 (en) 2013-03-28
PL203917B1 (pl) 2009-11-30
IL145043A (en) 2007-06-17
SI1162999T1 (sl) 2007-04-30
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
EP1776962A1 (en) 2007-04-25
TR200102739T2 (tr) 2001-12-21
NO330532B1 (no) 2011-05-09

Similar Documents

Publication Publication Date Title
BE2018C020I2 (US07585860-20090908-C00083.png)
BE2015C057I2 (US07585860-20090908-C00083.png)
BE2016C007I2 (US07585860-20090908-C00083.png)
BE2015C018I2 (US07585860-20090908-C00083.png)
BE2014C017I2 (US07585860-20090908-C00083.png)
BE2013C051I2 (US07585860-20090908-C00083.png)
BE2013C020I2 (US07585860-20090908-C00083.png)
BE2013C015I2 (US07585860-20090908-C00083.png)
BE2013C001I2 (US07585860-20090908-C00083.png)
BE2012C036I2 (US07585860-20090908-C00083.png)
BE2011C004I2 (US07585860-20090908-C00083.png)
BE2010C011I2 (US07585860-20090908-C00083.png)
LU91652I9 (US07585860-20090908-C00083.png)
BE2008C046I2 (US07585860-20090908-C00083.png)
JP2002514480A5 (US07585860-20090908-C00083.png)
BRPI0017527B8 (US07585860-20090908-C00083.png)
IN2001KO01233A (US07585860-20090908-C00083.png)
BE2008C047I2 (US07585860-20090908-C00083.png)
BRPI0001672A2 (US07585860-20090908-C00083.png)
JP2002521141A5 (US07585860-20090908-C00083.png)
JP2002521591A5 (US07585860-20090908-C00083.png)
JP2002517184A5 (US07585860-20090908-C00083.png)
JP2002519925A5 (US07585860-20090908-C00083.png)
JP2002513244A5 (US07585860-20090908-C00083.png)
JP2002506962A5 (US07585860-20090908-C00083.png)